PMID- 20498120
OWN - NLM
STAT- MEDLINE
DCOM- 20100916
LR  - 20220408
IS  - 1460-2091 (Electronic)
IS  - 0305-7453 (Linking)
VI  - 65
IP  - 7
DP  - 2010 Jul
TI  - Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy 
      compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 
      week ARTEMIS data.
PG  - 1505-9
LID - 10.1093/jac/dkq150 [doi]
AB  - OBJECTIVES: To examine how treatment adherence differences in ARTEMIS (96 week 
      analysis) affected clinical outcome, and to assess factors impacting adherence. 
      PATIENTS AND METHODS: ARTEMIS is a Phase III trial, in HIV-1-infected 
      treatment-naive patients, comparing efficacy and safety of once-daily 
      darunavir/ritonavir (800/100 mg) versus lopinavir/ritonavir (800/200 mg total 
      daily dose), each with a fixed-dose background tenofovir and emtricitabine 
      regimen. Self-reported treatment adherence was assessed using the Modified 
      Medication Adherence Self-Report Inventory (M-MASRI). In post-hoc analyses, mean 
      adherence from weeks 4-96 was used to assess overall adherence for each patient, 
      and transformed into a binary variable (>95% , adherent; < or = 95% , 
      suboptimally adherent). RESULTS: Overall adherence was high: 83% of 
      darunavir/ritonavir-treated patients and 78% of lopinavir/ritonavir-treated 
      patients were >95% adherent. The difference in virological response rate for 
      adherent versus suboptimally adherent patients was smaller for 
      darunavir/ritonavir (6% difference: 82% versus 76%, P = 0.3312) than for 
      lopinavir/ritonavir (25% difference: 78% versus 53%, P < 0.0001). In suboptimally 
      adherent patients, a higher virological response rate was seen with 
      darunavir/ritonavir (76%) versus lopinavir/ritonavir (53%) (P < 0.01). 
      Suboptimally adherent patients (both treatment groups) reported more adverse 
      events (AEs), including gastrointestinal AEs, than adherent patients. 
      Darunavir/ritonavir had a lower rate of AEs, including gastrointestinal AEs, than 
      lopinavir/ritonavir, in adherent and suboptimally adherent patients. CONCLUSIONS: 
      Suboptimal adherence had no significant effect on the virological response rate 
      with once-daily darunavir/ritonavir treatment. In contrast, the 
      lopinavir/ritonavir response rate was significantly reduced in suboptimally 
      adherent patients compared with adherent patients. Once-daily darunavir/ritonavir 
      resulted in a higher virological response rate in suboptimally adherent patients 
      compared with lopinavir/ritonavir.
FAU - Nelson, Mark
AU  - Nelson M
AD  - Chelsea and Westminster Hospital, London, UK. mark.nelson@chelwest.nhs.uk
FAU - Girard, Pierre-Marie
AU  - Girard PM
FAU - Demasi, Ralph
AU  - Demasi R
FAU - Chen, Liddy
AU  - Chen L
FAU - Smets, Erik
AU  - Smets E
FAU - Sekar, Vanitha
AU  - Sekar V
FAU - Lavreys, Ludo
AU  - Lavreys L
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100524
PL  - England
TA  - J Antimicrob Chemother
JT  - The Journal of antimicrobial chemotherapy
JID - 7513617
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Pyrimidinones)
RN  - 0 (Sulfonamides)
RN  - 2494G1JF75 (Lopinavir)
RN  - O3J8G9O825 (Ritonavir)
RN  - YO603Y8113 (Darunavir)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/*administration & dosage/adverse effects
MH  - Darunavir
MH  - HIV Infections/*drug therapy/virology
MH  - HIV-1/isolation & purification
MH  - Humans
MH  - Lopinavir
MH  - Medication Adherence/statistics & numerical data
MH  - Pyrimidinones/*administration & dosage/adverse effects
MH  - Ritonavir/*administration & dosage/adverse effects
MH  - Sulfonamides/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Viral Load
EDAT- 2010/05/26 06:00
MHDA- 2010/09/18 06:00
CRDT- 2010/05/26 06:00
PHST- 2010/05/26 06:00 [entrez]
PHST- 2010/05/26 06:00 [pubmed]
PHST- 2010/09/18 06:00 [medline]
AID - dkq150 [pii]
AID - 10.1093/jac/dkq150 [doi]
PST - ppublish
SO  - J Antimicrob Chemother. 2010 Jul;65(7):1505-9. doi: 10.1093/jac/dkq150. Epub 2010 
      May 24.